OBJECTIVE: The economic profile of acute myeloid leukaemia (AML) is badly known. The few studies published on this disease are now relatively old and include small numbers of patients. The purpose of this retrospective study was to evaluate the induction-related cost of 500 patients included in the AML 2001 trial, and to determine the explanatory factors of cost. SETTING: "Induction" patient's hospital stay from admission for "induction" to discharge after induction. METHOD: The study was performed from the French Public Health insurance perspective, restrictive to hospital institution costs. The average management of a hospital stay for "induction" was evaluated according to the analytical accounting of Besançon University Teaching Hospital and the French public Diagnosis-Related Group database. Multiple linear regression was used to search for explanatory factors. MAIN OUTCOME MEASURE: Only direct medical costs were included: treatment and hospitalisation. RESULTS: Mean induction-related direct medical cost was estimated at €41,852 ± 6,037, with a mean length of hospital stay estimated at 36.2 ± 10.7 days. After adjustment for age, sex and performance status, only two explanatory factors were found: an additional induction course and salvage course increased induction-related cost by 38% (± 4) and 15% (± 1) respectively, in comparison to one induction. These explanatory factors were associated with a significant increase in the mean length of hospital stay: 45.8 ± 11.6 days for 2 inductions and 38.5 ± 15.5 if the patient had a salvage course, in comparison to 32.9 ± 7.7 for one induction (P < 10⁻⁴). This result is robust and was confirmed by sensitivity analysis. CONCLUSION: Consideration of economic constraints in health care is now a reality. Only the control of length of hospital stay may lead to a decrease in induction-related cost for patients with AML.
OBJECTIVE: The economic profile of acute myeloid leukaemia (AML) is badly known. The few studies published on this disease are now relatively old and include small numbers of patients. The purpose of this retrospective study was to evaluate the induction-related cost of 500 patients included in the AML 2001 trial, and to determine the explanatory factors of cost. SETTING: "Induction" patient's hospital stay from admission for "induction" to discharge after induction. METHOD: The study was performed from the French Public Health insurance perspective, restrictive to hospital institution costs. The average management of a hospital stay for "induction" was evaluated according to the analytical accounting of Besançon University Teaching Hospital and the French public Diagnosis-Related Group database. Multiple linear regression was used to search for explanatory factors. MAIN OUTCOME MEASURE: Only direct medical costs were included: treatment and hospitalisation. RESULTS: Mean induction-related direct medical cost was estimated at €41,852 ± 6,037, with a mean length of hospital stay estimated at 36.2 ± 10.7 days. After adjustment for age, sex and performance status, only two explanatory factors were found: an additional induction course and salvage course increased induction-related cost by 38% (± 4) and 15% (± 1) respectively, in comparison to one induction. These explanatory factors were associated with a significant increase in the mean length of hospital stay: 45.8 ± 11.6 days for 2 inductions and 38.5 ± 15.5 if the patient had a salvage course, in comparison to 32.9 ± 7.7 for one induction (P < 10⁻⁴). This result is robust and was confirmed by sensitivity analysis. CONCLUSION: Consideration of economic constraints in health care is now a reality. Only the control of length of hospital stay may lead to a decrease in induction-related cost for patients with AML.
Authors: M Clavio; S Quintino; B Masoudi; S Carrara; R Cerri; I Pierri; L Canepa; M Miglino; P Muner; E Damasio; M Gobbi Journal: J Exp Clin Cancer Res Date: 2001-06
Authors: Alberto Redaelli; Marc F Botteman; Jennifer M Stephens; Suzanne Brandt; Chris L Pashos Journal: Cancer Treat Rev Date: 2004-05 Impact factor: 12.111
Authors: Jennifer E Vaughn; Megan Othus; Morgan A Powell; Kelda M Gardner; Donelle L Rizzuto; Paul C Hendrie; Pamela S Becker; Paul S Pottinger; Elihu H Estey; Roland B Walter Journal: JAMA Oncol Date: 2015-11 Impact factor: 31.777
Authors: Roland B Walter; Lenise R Taylor; Kelda M Gardner; Kathleen Shannon Dorcy; Jennifer E Vaughn; Elihu H Estey Journal: Clin Adv Hematol Oncol Date: 2013
Authors: Sarah Bertoli; Pierre Bories; Marie C Béné; Sylvie Daliphard; Bruno Lioure; Arnaud Pigneux; Norbert Vey; Jacques Delaunay; Vincent Leymarie; Isabelle Luquet; Odile Blanchet; Pascale Cornillet-Lefebvre; Mathilde Hunault; Didier Bouscary; Nathalie Fegueux; Philippe Guardiola; François Dreyfus; Jean Luc Harousseau; Jean Yves Cahn; Norbert Ifrah; Christian Récher Journal: Haematologica Date: 2013-08-23 Impact factor: 9.941
Authors: O Türeci; U Sahin; H Schulze-Bergkamen; Z Zvirbule; F Lordick; D Koeberle; P Thuss-Patience; T Ettrich; D Arnold; F Bassermann; S E Al-Batran; K Wiechen; K Dhaene; D Maurus; M Gold; C Huber; A Krivoshik; A Arozullah; J W Park; M Schuler Journal: Ann Oncol Date: 2019-09-01 Impact factor: 32.976